Single-Dose HPV Vaccine Evaluation Consortium
Accumulating evidence shows that a single-dose of human papillomavirus (HPV) vaccine elicits a strong immune response to protect against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.
Clinical trials, observational studies, and modeling analyses are ongoing to evaluate the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single-dose HPV vaccination. Data accumulated to date provide strong evidence that a single-dose regimen could substantially reduce the incidence of HPV-attributable cervical precancer and cancer. Single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs. For low- and middle-income countries that have delayed introducing HPV vaccines because of financial, logistical or other barriers; a single-dose HPV vaccination schedule could accelerate introduction of HPV vaccines into national immunization schedules.
The Single-Dose HPV Vaccine Evaluation Consortium encompasses eight leading independent research institutions working together to collate and synthesize existing evidence and evaluate new data on the potential for single-dose HPV vaccination. The consortium’s goal is to evaluate this evidence over the course of the project (2018–2023) to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications.
Publications on single-dose HPV vaccination
- Efficacy of single-dose HPV vaccination among young African women. NEJM Evidence. April 2022
- Immunogenicity and Safety Results Comparing Single Dose Human Papillomavirus Vaccine with Two or Three Doses in Tanzanian Girls - the DoRIS Randomised Trial. Preprint. March 2022.
- Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials. Preprint. March 2022.
- Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncology. November 2021.
- Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute. October 2020.
- Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine. February 2021.
- Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. Human Vaccines & Immunotherapeutics. December 2019.
- Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. December 2019.
- Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. The Journal of Infectious Diseases. November 2019.
- Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. The Lancet Oncology. November 2019, Volume 20, Issue 11, Pages e637-e644
- Preventing Cervical Cancer: How much HPV Vaccine do we need? Vaccine. August 2018, Volume 36, Issue 32, Part A, Pages 4759-4836
- Can we use one dose of HPV vaccine to ensure long term protection? HPV World. September 2017, Year 1, No 23-31.